Application of neoadjuvant therapy in the treatment of esophageal cancer

Abstract

Bu Qian, Huang Junxing. Application of neoadjuvant therapy in the treatment of esophageal cancer[J]. Journal of International Oncology, 2020, 47(4): 244-248.

References27

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.v68.6
[2]	Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
[3]	汪楣, 谷铣之, 黄国俊 , 等. 食管癌术前放射治疗的前瞻性临床研究[J]. 中华放射肿瘤学杂志, 2001,10(3):168-171. DOI: 10.3760/j.issn:1004-4221.2001.03.007.
[4]	Thumallapally N, Meshref A, Mousa M , et al. Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis[J]. J Gastrointest Oncol, 2017,8(5):825-832. DOI: 10.21037/jgo.2017.06.19.
[5]	Chan KKW, Saluja R, Delos Santos K , et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis[J]. Int J Cancer, 2018,143(2):430-437. DOI: 10.1002/ijc.31312.
[6]	谭黎杰, 汪灏, 唐汉 . 局部进展期食管癌新辅助治疗的现状与展望[J]. 中华消化外科杂志, 2017,16(5):450-453. DOI: 10.3760/cma.j.issn.1673-9752.2017.05.003.
[7]	闫海霞, 符国胜 . 术前放疗对食管癌患者影响的临床分析[J]. 当代医学, 2011,17(16):21-22. DOI: 10.3969/j.issn.1009-4393.2011.16.014.
[8]	Zhu Y, Liu M, Yun X , et al. Meta-analysis for the therapeutic effect of neoadjuvant therapy in resectable esophageal cancer[J]. Pathol Oncol Res, 2017,23(3):657-663. DOI: 10.1007/s12253-016-0164-4.
[9]	Hara H, Tahara M, Daiko H , et al. Phase Ⅱ feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma[J]. Cancer Sci, 2013,104(11):1455-1460. DOI: 10.1111/cas.12274.
[10]	Pasquali S, Yim G, Vohra RS , et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis[J]. Ann Surg, 2017,265(3):481-491. DOI: 10.1097/SLA.000000000000-1905.
[11]	Ma S, Yan T, Liu D , et al. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma[J]. Thoracic Cancer, 2018,9(2):310-315. DOI: 10.1111/1759-7714.12590.
[12]	Zheng Y, Li Y, Liu X , et al. Reevaluation of neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials over the past 20 years[J]. Medicine (Baltimore), 2015,94(27):e1102. DOI: 10.1097/MD.0000000000001102.
[13]	Tanaka K, Miyata H, Sugimura K , et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts[J]. Carcinogenesis, 2015,36(8):894-903. DOI: 10.1093/carcin/bgv067.
[14]	Yoshida N, Baba Y, Shigaki H , et al. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2016,21(6):1071-1078. DOI: 10.1007/s10147-016-0994-9.
[15]	van Hagen P, Hulshof MC, van Lanschot JJ , et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. New Engl J Med, 2012,366(22):2074-2084. DOI: 10.1056/NEJMoa1112088.
[16]	Shapiro J, van Lanschot JJB, Hulshof MCCM , et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015,16(9):1090-1098. DOI: 10.1016/s1470-2045(15)00040-6.
[17]	Mantziari S, Gronnier C, Renaud F , et al. Survival benefit of neoadjuvant treatment in clinical T₃N₀M₀esophageal cancer: results from a retrospective multicenter European study[J]. Ann Surg, 2017,266(5):805-813. DOI: 10.1097/SLA.000000000000-2402.
[18]	Yang H, Liu H, Chen Y , et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2097-2083. DOI: 10.1200/JCO.2018.79.1483.
[19]	刘施亮, 习勉, 杨雅迪 , 等. 局部晚期食管鳞癌新辅助放化疗联合手术治疗的临床疗效分析[J]. 中华放射肿瘤学杂志, 2015,24(3):232-236. DOI: 10.3760/cma.j.issn.1004-4221.2015.03.002. doi:10.3760/cma.j.issn.1004-4221.2015.03.002
[20]	Hamai Y, Hihara J, Taomoto J , et al. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer[J]. Dis Esophagus, 2015,28(4):358-364. DOI: 10.1111/dote.12207.
[21]	Ychou M, Boige V, Pignon JP , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011,29(13):1715-1721. DOI: 10.1200/JCO.2010.33.0597.
[22]	Ronellenfitsch U, Schwarzbach M, Hofheinz R , et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data[J]. Eur J Cancer, 2013,49(15):3149-3158. DOI: 10.1016/j.ejca.2013.05.029. doi:10.1016/j.ejca.2013.05.029
[23]	Alderson D, Cunningham D, Nankivell M , et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2017,18(9):1249-1260. DOI: 10.1016/s1470-2045(17)30447-3.
[24]	Kumagai K, Rouvelas I, Tsai JA , et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis[J]. Eur J Surg Oncol, 2015,41(3):282-294. DOI: 10.1016/j.ejso.2014.11.039.
[25]	Stahl M, Walz MK, Riera-Knorrenschild J , et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial[J]. Eur J Cancer, 2017,81:183-190. DOI: 10.1016/j.ejca.2017.04.027. doi:10.1016/j.ejca.2017.04.027
[26]	Deng HY, Wang WP, Wang YC , et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer[J]. Eur J Cardiothorac Surg, 2017,51(3):421-431. DOI: 10.1093/ejcts/ezw315.
[27]	Bibby BA, Reynolds JV, Maher SG . MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma[J]. PLoS One, 2015,10(7):e0134180. DOI: 10.1371/journal.pone.0134180.

Application of neoadjuvant therapy in the treatment of esophageal cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References27

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[3]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[4]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[5]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[6]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer.Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition）[J]. Journal of International Oncology, 2023, 50(7): 385-397.
[7]	Xu Fang, Zhu Wentian.Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion[J]. Journal of International Oncology, 2023, 50(5): 304-309.
[8]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong.Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer[J]. Journal of International Oncology, 2023, 50(2): 76-81.
[9]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng.Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750.
[10]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[11]	Xie Yu, Zheng Shengnan, Huang Mingmin, Guo Aibin, Yin Zhenyu, Lin Yongjuan.Pemetrexed clinical trial for intrathecal injection chemotherapy based on cerebrospinal fluid pharmacokinetics in patients with leptomeningeal metastasis from lung adenocarcinoma[J]. Journal of International Oncology, 2023, 50(10): 585-591.
[12]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei.Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(8): 464-472.
[13]	Lin Yongjuan, Li Huiying, Yin Zhenyu, Guo Aibin, Xie Yu.Investigation of cerebrospinal fluid metabolites in patients with leptomeningeal metastases from lung adenocarcinoma based on untargeted metabolomics[J]. Journal of International Oncology, 2022, 49(7): 390-399.
[14]	Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian.Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN₊esophageal squamous cell carcinoma patients[J]. Journal of International Oncology, 2022, 49(6): 334-339.
[15]	Cai Gangxiang, Li Jing, Xu Bin.Advances in neoadjuvant immunotherapy for lung cancer[J]. Journal of International Oncology, 2022, 49(6): 366-370.